{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/herpes-simplex-oral/","result":{"data":{"firstChapter":{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field c28e53c9-19a8-4752-8f9e-a3420646bbcd --><h1>Herpes simplex - oral: Summary</h1><!-- end field c28e53c9-19a8-4752-8f9e-a3420646bbcd -->","htmlStringContent":"<!-- begin item 697c2f1f-583d-49b6-a9c3-a7290a67282f --><!-- begin field bd868bfb-4665-408b-97ca-e28eac5823e2 --><ul><li>Oral herpes simplex virus (HSV) usually causes a mild, self-limiting infection of the lips, cheeks, or nose (herpes labialis or 'cold sores') or oropharyngeal mucosa (gingivostomatitis).<ul><li>Herpes simplex virus type 1 (HSV-1) is the cause in more than 90% of cases. Rarely, infections may be caused by HSV-2.</li><li>Most HSV-1 infections are subclinical and asymptomatic.</li><li>Symptomatic primary infection usually presents as gingivostomatitis in children.</li></ul></li><li>HSV-1 is usually transmitted via direct contact with infected secretions entering via the skin or mucous membranes, from a person who is actively shedding the virus.</li><li>Oral HSV infection can cause severe or life-threatening complications, particularly in immunocompromised people, including eczema herpeticum, eye disease including corneal ulceration, erythema multiforme, pneumonia, and encephalitis.</li><li>Primary herpes labialis lesions usually resolve within 10–14 days; gingivostomatitis usually heals within 2–3 weeks.</li><li>The diagnosis of oral herpes simplex is based on the person's age and clinical features, such as the history, location, and appearance of lesions.<ul><li>Herpes labialis may present with a prodrome of fever, sore throat, and lymphadenopathy, particularly in primary infections.</li><li>Initial symptoms of pain, burning, tingling, and itching may precede visible lesions and typically last 6–48 hours.</li><li>Herpes labialis lesions are typically crops of vesicles that rupture, ulcer, crust, and heal (usually without scarring).</li><li>Herpes gingivostomatitis lesions are typically crops of painful vesicles that rupture and form ulcers on the pharyngeal and oral mucosa.</li><li>People who are immunocompromised may have severe, atypical lesions anywhere in the oral cavity.</li></ul></li><li>Assessment of a person with suspected oral herpes simplex should include:<ul><li>Any known trigger factors, such as ultraviolet light, stress, fever, or trauma to the area.</li><li>Any red flags for oral cancer.</li></ul></li><li>Investigations are not usually needed in primary care.</li><li>Management of a person with suspected oral herpes simplex should include:<ul><li>Arranging hospital admission if the person is unable to swallow or is dehydrated; is immunocompromised with severe infection; or a serious complication is suspected.</li><li>Seeking specialist advice or referral if the person is immunocompromised with troublesome infection; is pregnant; has frequent, persistent, or severe infections; has associated recurrent erythema multiforme; lesions are refractory to primary care treatment; or lesions are atypical. </li></ul></li><li>Management of oral herpes simplex infection includes:<ul><li>Offering analgesia to treat pain and fever, if needed.</li><li>Considering prescribing an episodic oral antiviral such as aciclovir or valaciclovir, for healthy people with a primary or recurrent infection if lesions are frequent, persistent, or severe; people with recurrent gingivostomatitis; and people who are immunocompromised with primary or recurrent infection, depending on clinical judgement.</li><li>Advising that topical antiviral preparations, topical analgesics, mouthwash and lip barrier preparations are not routinely recommended, but some people may find them helpful, and they are available over-the-counter.</li><li>Offering self-care advice to avoid trigger factors, if possible, and to reduce the risk of autoinoculation and transmission to other people.</li><li>The use of sunscreen or sunblock lip balm for people with recurrent infections triggered by sunlight.</li></ul></li></ul><!-- end field bd868bfb-4665-408b-97ca-e28eac5823e2 --><!-- end item 697c2f1f-583d-49b6-a9c3-a7290a67282f -->","topic":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b","topicId":"5f875f0c-db78-44fb-b672-bd54c9216205","topicName":"Herpes simplex - oral","slug":"herpes-simplex-oral","aliases":[],"chapters":[{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"83c52d0f-97ef-5a31-8ff4-41d30aff63ad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes"},{"id":"96fd5acc-0417-54f9-8185-fd7234a33908","slug":"update","fullItemName":"Update"}]},{"id":"56d4e2ce-1a2c-5bbf-9a02-d7ec1fe80537","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"abbdfc66-bff5-502d-ad7d-32c81000d0f2","slug":"goals","fullItemName":"Goals"},{"id":"b3a9824a-ae33-5fa9-81e7-a932b005c125","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f2bb54c7-b5b0-5b30-a704-921dce3f32c9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d3f7ec4d-ecc0-5956-b6b6-22c492e1122f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9944dadf-7acf-5f24-8f20-c050c044edba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"425c65b2-de3b-5863-b73c-72199baee6f1","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"5749e0ab-cd7c-5a50-bc2c-ef816e9599c2","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"1d630313-1e41-59ae-8ae9-5cd26302276f","slug":"definition","fullItemName":"Definition"},{"id":"31a0a436-27cb-58e7-949b-76fb6dbd9c54","slug":"transmission","fullItemName":"Transmission"},{"id":"98ffdaac-76d5-54c1-93f5-7dd4a2f9148b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf160e19-7acf-5ed0-9c7a-be8eeb5b5d1c","slug":"complications","fullItemName":"Complications"},{"id":"739ee047-f37b-56ca-ae40-7c3875158ee6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"bc2ab338-32ce-50dc-8b2b-3546b85d2d9f","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"78e575da-c305-5bf9-b61a-f062ae2c4eb5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e37bcee1-69de-5e61-9294-81ff5642fa57","slug":"assessment","fullItemName":"Assessment"},{"id":"ed37f634-077a-5cf4-880d-5d2e9e5e5d9c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","slug":"management","fullItemName":"Management","subChapters":[{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis"}]},{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"8416d8f1-2061-51a1-b6ab-29d314b7738e","slug":"analgesia","fullItemName":"Analgesia"},{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs"}]},{"id":"3a06d913-863d-5a7d-a6ce-6f327e1db685","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"981bfc0e-bf2d-528d-a298-5ed824004d46","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d4db274b-f8f9-559e-8053-48f1712ad1f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1ee8a0ab-5883-561f-9aed-2524df466dfb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1c48988f-4b5b-512c-90dc-8f7341fd9a0f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e1757009-f8a2-561e-9c49-0048e0c195b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9fbce5d9-f27e-5f7c-8744-4b00ad58e71d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5966d8c-2014-541a-bd9b-fbab33577d44","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b","topicId":"5f875f0c-db78-44fb-b672-bd54c9216205","topicName":"Herpes simplex - oral","slug":"herpes-simplex-oral","aliases":[],"topicSummary":"Oral herpes simplex virus (HSV) usually causes a mild, self-limiting infection of the lips, cheeks, nose or oropharynx","lastRevised":"Last revised in October 2016","nextPlannedReviewBy":"2021-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2021-09","nextPlannedReviewByDisplay":"September 2021","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"ffd5e44f-8711-5d16-b86e-191d194288ec","name":"Oral health","slug":"oral-health"}],"chapters":[{"id":"2106bbf3-357c-5e99-8faf-4898c1ca935e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"83c52d0f-97ef-5a31-8ff4-41d30aff63ad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"88707caf-63e9-5b1e-bd0d-adca6b1e4d1b","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"0b1ea486-a30d-554a-87c3-68b2a981d26d","slug":"changes","fullItemName":"Changes"},{"id":"96fd5acc-0417-54f9-8185-fd7234a33908","slug":"update","fullItemName":"Update"}]},{"id":"56d4e2ce-1a2c-5bbf-9a02-d7ec1fe80537","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"abbdfc66-bff5-502d-ad7d-32c81000d0f2","slug":"goals","fullItemName":"Goals"},{"id":"b3a9824a-ae33-5fa9-81e7-a932b005c125","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f2bb54c7-b5b0-5b30-a704-921dce3f32c9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d3f7ec4d-ecc0-5956-b6b6-22c492e1122f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9944dadf-7acf-5f24-8f20-c050c044edba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"425c65b2-de3b-5863-b73c-72199baee6f1","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"5749e0ab-cd7c-5a50-bc2c-ef816e9599c2","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"1d630313-1e41-59ae-8ae9-5cd26302276f","slug":"definition","fullItemName":"Definition"},{"id":"31a0a436-27cb-58e7-949b-76fb6dbd9c54","slug":"transmission","fullItemName":"Transmission"},{"id":"98ffdaac-76d5-54c1-93f5-7dd4a2f9148b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bf160e19-7acf-5ed0-9c7a-be8eeb5b5d1c","slug":"complications","fullItemName":"Complications"},{"id":"739ee047-f37b-56ca-ae40-7c3875158ee6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"bc2ab338-32ce-50dc-8b2b-3546b85d2d9f","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"78e575da-c305-5bf9-b61a-f062ae2c4eb5","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e37bcee1-69de-5e61-9294-81ff5642fa57","slug":"assessment","fullItemName":"Assessment"},{"id":"ed37f634-077a-5cf4-880d-5d2e9e5e5d9c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ca77797d-b745-54df-ae5b-ca78f5b20941","slug":"management","fullItemName":"Management","subChapters":[{"id":"3270af1a-6907-5c03-9ffb-c4d827c56103","slug":"herpes-labialis-gingivostomatitis","fullItemName":"Scenario: Herpes labialis and gingivostomatitis"}]},{"id":"059e9ce0-0874-50ea-b177-6ae9c92398c4","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"8416d8f1-2061-51a1-b6ab-29d314b7738e","slug":"analgesia","fullItemName":"Analgesia"},{"id":"eeff86e7-c71a-5781-a929-0698c0bcfc16","slug":"oral-antiviral-drugs","fullItemName":"Oral antiviral drugs"}]},{"id":"3a06d913-863d-5a7d-a6ce-6f327e1db685","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"981bfc0e-bf2d-528d-a298-5ed824004d46","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d4db274b-f8f9-559e-8053-48f1712ad1f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1ee8a0ab-5883-561f-9aed-2524df466dfb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1c48988f-4b5b-512c-90dc-8f7341fd9a0f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e1757009-f8a2-561e-9c49-0048e0c195b9","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9fbce5d9-f27e-5f7c-8744-4b00ad58e71d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5966d8c-2014-541a-bd9b-fbab33577d44","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"401dad14-da6a-5b54-bb3d-2cfea5661d4b"}},"staticQueryHashes":["3666801979"]}